Sarepta Therapeutics (SRPT) Tops Q2 EPS by 25c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Sarepta Therapeutics Announces Second Quarter 2020 Financial Results and Recent Corporate Developments
August 5, 2020 4:05 PM EDTNet product sales of $111.3 million, an 18% increase over same quarter of prior year
CAMBRIDGE, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter of 2020.
I am pleased to report that, notwithstanding the distracting nature of the COVID-19 pandemic, Sarepta has continued to serve our patient community, achieving net product sales of $111.3 million, an 18% increase over the same quarter last year. And even as the majority of our workforce continued in a... More
